Announcement on the Approval Notice for Clinical Trial of Innovative Drug BIOS0629-109 Tablets

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd.·July 2, 2026·2 pages

✨ AI Summary

Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. announced that its innovative drug BIOS0629-109 tablets, jointly developed with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd., have received NMPA approval for clinical trials. The drug is intended for the treatment of advanced malignant tumors. This approval is a significant step in the drug's development, though it will not materially impact the company's short-term performance.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 301096

Securities Abbreviation: Baicheng Pharmaceutical

Announcement No.: 2026-034

Announcement of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. on the Approval Notice for Clinical Trial of Innovative Drug BIOS0629-109 Tablets

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.

Recently, Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") and Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Zhongshen Innovation") have jointly developed the innovative drug BIOS0629-109 tablets, which have received the clinical trial approval notice from the National Medical Products Administration (NMPA). The situation is hereby announced as follows:

I. Basic Information of the Drug

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.